The present invention relates to a new needle-form crystalline cabergoline form L its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and its use in pharmaceutical composition.

Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments provided herein are methods of treatment prevention or amelioration of a variety of medical disorders such as for example Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments provided herein are methods of antagonizing the 5-HT2B receptor and 5-HT2C receptors the using the compounds and compositions disclosed herein.

Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B receptor and 5-HT2C receptors the using the compounds and compositions disclosed herein.

ABSTRACT - 596297 The disclosure relates to a use of a biocompatible and/or biodegradable polymer and an effective amount of a dopamine modulating compound in the manufacture of a biodegradable implant for treating a subject for a dopamine associated state wherein said dopamine modulating compound is a dopamine agonist selected from the group consisting of apomorphine lisuride pergolide bromocriptine pramipexole rotigotine docarpamine terguride cabergoline levodopa spheramine romergoline carmoxi...

585621 Disclosed is the use of a dopamine agonist in the manufacture of a medicament for preventing or reducing weight gain associated with administration of an atypical antipsychotic drug wherein the medicament when administered is administered simultaneously or sequentially with the atypical antipsychotic drug wherein the dopamine agonist is selected from the group consisting of pramipexole bromocriptine cabergoline pergolide ropinirole and quinagolide and wherein the atypical antipsychotic dr...

592288 Disclosed is the use of a veterinary composition comprising at least one compound agonist of dopamine receptors for inducing the reduction antiprolactinic of lactation of ruminants and promoting mammary involution wherein said antiprolactinic compound agonist of dopamine receptors is selected from ergoline-derived dopamine receptor agonists chosen from amongst cabergoline metergoline lisurdine bromocriptine or ergometrine and/or non ergoline-derived dopamine receptor agonists chosen from ...

The present invention relates to a cabergoline crystal form L its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.

The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline crystal form is prepared by recovery from a solvate of cabergoline by drying or with desolvating in a solvent media.

The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed is a method for preparing cabergoline form I by combining cabergoline and a fist solvent to form a solution and additionally including a second solvent to the solution followed by crystallisation to form cabergoline form I. Further disclosed is a solvate form of cabergoline comprising caber...